Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL989183

O=C(O)C(F)(F)F.O=S(=O)(CC1CC1)NCc1ccc2c(c1)C(C1(c3ccccn3)CCC1)NCC2

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 7/20 0.38
CYP3A4 P08684 1/20 0.38
KDM1A O60341 6/20 0.35
KCNH2 Q12809 1/20 0.34
GAK O14976 1/20 0.32
STK16 O75716 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
CDKL2 Q92772 1/20 0.32
BMP2K Q9NSY1 1/20 0.32
CNR2 P34972 1/20 0.32
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
JAK3 P52333 1/20 0.31
OPRM1 P35372 1/20 0.31
PRCP P42785 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12096077 0.93 SLC6A9 (0.41) SLC6A9CYP3A4KCNH2GAKSTK16
Trifluoroacetic Acid SCHEMBL1857693 0.91 SLC6A9 (0.48) SLC6A9CYP3A4KDM1AJAK1
Trifluoroacetic Acid SCHEMBL989021 0.91 SLC6A9 (0.48) SLC6A9CYP3A4KDM1AJAK1
SCHEMBL8017098 0.83 SLC6A9 (0.52) SLC6A9CYP3A4JAK1
SCHEMBL989184 0.82 SLC6A9 (0.34) SLC6A9CYP3A4
SCHEMBL1857698 0.75 SLC6A9 (0.41) SLC6A9CYP3A4
SCHEMBL989947 0.72 SLC6A9 (0.60) SLC6A9CYP3A4OPRM1
SCHEMBL12096323 0.72 SLC6A9 (0.59) SLC6A9CYP3A4KCNH2
SCHEMBL8029655 0.71 SLC6A9 (0.72) SLC6A9CYP3A4KCNH2
Hydrochloric Acid SCHEMBL988975 0.71 SLC6A9 (0.59) SLC6A9CYP3A4KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653100-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2014-02-18 US disclosed
EP-2271625-B1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO KG (DE) 2012-09-12 EP disclosed
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott BmbH & Co. KG (DE) 2011-05-05 US disclosed
EP-2271625-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott GmbH & Co. KG (DE) 2011-01-12 EP disclosed
WO-2009121872-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO. KG (DE) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GOLT1B, SLC10A1, SUGT1 SLC6A9 73/4885CYP3A4 328/4885KDM1A 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.